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Objective To determine whether whole genome sequencing (WGS) can be used to define the 
molecular basis of suspected mitochondrial disease. 
Design Patients with suspected mitochondrial disorders were recruited to the 100,000 
Genomes Project in England between 2015 and 2018.   
Setting A multicentre study in the National Health Service in England including secondary 
and tertiary care.   
Participants 319 families with suspected mitochondrial disease were referred for WGS after 
excluding common genetic causes. 345 affected individuals were recruited (186 female, 159 
male), with median age 25 years (range 0 to 92). Trio or quad analysis with both parents was 
performed in 148 families (46%). Clinical information was collected systematically using 
Human Phenotype Ontology (HPO) terms with a median of 7 HPO terms per participant.  
Commonest HPO terms were delayed gross motor development, intellectual disability, 
myopathy, seizures and ptosis.  
Intervention:  Short-read whole genome sequencing was performed.  Nuclear variants were 
prioritised based on gene panels chosen according to phenotypes, ClinVar pathogenic/likely 
pathogenic variants, and the top ten prioritised variants from Exomiser. mtDNA variants 
were called using an in-house pipeline and compared to a list of pathogenic variants.  Copy 
number variants and short tandem repeats for thirteen neurological disorders were also 
analysed.  ACMG guidelines were followed for the classification of variants. 
Main Outcome Measures:  Finding a definite or probable genetic diagnosis.   
Results: A definite or probable genetic diagnosis was identified in 98 families (31%), with an 
additional 6 possible diagnoses (2%).   Fourteen of the diagnoses (4% of the 98 families) 
explained only part of the clinical features.  A total of 95 different genes were implicated.  
37.5% of diagnosed families had a mitochondrial diagnosis and 62.5% had a non-
mitochondrial diagnosis. 
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Conclusion WGS is a useful diagnostic test in patients with suspected mitochondrial 
disorders yielding a diagnosis in a further 31% after excluding common causes.  The majority 
of diagnoses were non-mitochondrial disorders and included developmental disorders with 
intellectual disability, epileptic encephalopathies, other metabolic disorders, 
cardiomyopathies and leukodystrophies. These would have been missed if a targeted 




What is already know on this topic 
• Mitochondrial disorders are amongst the most common inherited diseases, but a 
genetic diagnosis is not possible in ~40% of patients, limiting genetic counselling and 
prevention. 
• Whole genome sequencing (WGS) has the potential to shorten the “diagnostic 
odyssey” for patients with suspected mitochondrial disorders, but its use in a national 
healthcare system has not been previously investigated. 
What this study adds 
• After excluding common genetic causes, WGS identified a definite or probable 
genetic diagnosis in an additional 31% of patients (including 4% with partial 
diagnoses), and an additional 2% had possible diagnoses. 
• 62.5% of the newly diagnosed families had a non-mitochondrial diagnosis showing 
that a wide genomic approach is more useful than a targeted panel testing approach. 





Mitochondrial disorders have emerged as a common cause of inherited metabolic disease 
affecting ~1 in 5000 people1 and  are caused by mutations in genes which primarily affect 
oxidative phosphorylation and ATP synthesis2.  Mitochondria are intra-cellular organelles 
which play a pivotal role in cellular energy metabolism. This is achieved by  a series of 
complex enzymes located in the inner mitochondrial membrane which perform oxidative 
phosphorylation and synthesise adenosine triphosphate (ATP). ATP is a chemical source of 
energy required for all active cellular processes. The impairment of mitochondrial function 
tends to affect tissues with high energy demand such as the brain, the peripheral nerves, the 
eye, the heart and the peripheral muscles.  The clinical diagnosis of mitochondrial disorders 
is challenging because they can affect a single organ such as the eye in Leber Hereditary 
Optic Neuropathy3, or many different systems, and they can present at any age.  Although 
some patients present with a classical mitochondrial syndrome, such as mitochondrial 
encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), many present 
with only one or a few of the clinical features (oligosymptomatic cases)4 or with an ill-
defined multi-system disorder.  Mitochondria contain their own DNA in the form of a small 
16.5kb circle of double stranded DNA (mtDNA), which encodes for 13 peptides, two 
ribosomal RNAs and 22 transfer RNAs which are essential for synthesising proteins within 
the organelle.  However, the vast majority of proteins making up the mitochondria are 
encoded by genes in the nucleus and are synthesised in the cytosol before being imported 
through a bespoke import machinery.  Mitochondrial disorders can be caused by pathogenic 
variants in either the mtDNA or the nuclear genome, can follow any inheritance pattern 
(autosomal dominant, autosomal recessive, X-linked, de novo or maternal) and are highly 
genetically heterogeneous5. For example, Leigh syndrome, the commonest childhood 
presentation of mitochondrial disease which usually presents in the first year of life with 
stepwise loss of skills, is caused by mutations in ~100 nuclear and mtDNA genes6.  These 
challenges often result in a prolonged patient journey from symptom onset to reaching a 
diagnosis, referred to as a “diagnostic odyssey”7,8.  In patients with rare diseases, this 
typically involves multiple appointments - first in primary care, then with different specialist 
services - and many investigations, sometimes over many years.  One survey8 found that 
patients saw an average of 8 physicians before being diagnosed with a mitochondrial disease, 
and 70% had a muscle biopsy.  
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The diagnosis of mitochondrial disease has traditionally relied on an invasive tissue biopsy 
for biochemical and histochemical analysis9, which can be normal even in patients with a 
defined genetic diagnosis. Sequencing a pre-defined list of genes known to cause a specific 
disorder (multi-gene panels), and sequencing of the protein-coding regions (exons) of all 
genes (exome sequencing), have been effective for diagnosing mitochondrial disorders10–16 
and in discovering new mitochondrial disease genes. However, it is still not possible to make 
a genetic diagnosis in ~40%10 even in highly selected cohorts, hence the need for new 
approaches.   
A definitive genetic diagnosis benefits patients and families17, allowing tailored information 
about prognosis and treatment, genetic counselling and access to reproductive options such as 
prenatal diagnosis (genetic testing during pregnancy – usually by chorionic villus sampling or 
amniocentesis), pre-implantation genetic diagnosis (the use of assisted reproductive 
technology and genetic testing of embryos), and mitochondrial transfer (replacing the 
mother’s mitochondria in an ovum or early embryo with healthy mitochondria from another 
woman’s donor egg or embryo, used for disorders caused by mtDNA mutations)18.  Whole 
genome sequencing (WGS) is a next-generation sequencing technology that is used to 
sequence the entire genome of an individual. WGS has the added benefit of being able to 
diagnose pathogenic mutations affecting the mtDNA and the nuclear genome19, and thus has 
the potential to make a diagnosis in more families and shorten the time to diagnosis20. The 
objective of this study was to see if whole genome sequencing could be used to define the 
molecular basis of suspected mitochondrial disorders in a national health care system in 
patients assessed in mainstream secondary care as well as tertiary centres. The 100,000 
Genomes Project was set up to introduce and embed genomic testing into the mainstream 
National Health Service (NHS), discover new disease genes and make genetic diagnosis 
available for more patients21.  Following an initial pilot phase22, patients in the 100,000 
Genomes Project were recruited from NHS Genomic Medicine Centres (GMCs) across 
England. Here, we report the results for 345 patients with a suspected mitochondrial disorder 
recruited into the main programme between 2015 and 2018. 
Materials and Methods 
Participants 
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Participants with suspected mitochondrial disorders were recruited to the 100,000 Genomes 
Project (main programme) between 2015 and 2018 with an unexplained multi-system 
progressive disorder usually involving the central nervous system and/or neuromuscular 
system.  All participants provided written informed consent and the study was approved by 
the HRA Committee East of England Cambridge South (REC Ref 14/EE/1112). Eligibility 
criteria stated that mtDNA and common nuclear genetic causes (e.g. POLG mutations) 
should have been excluded (full inclusion criteria in Supplementary Methods). All 
participants recruited under the category ‘Suspected Mitochondrial Disorder’ who had 
Tiering data available in data release v8_2019-11-28 were included in the study.   In 2015-
2018, genetic testing in the UK was arranged through 20 regional genetics laboratories, and 
there were three NHS highly specialised services for rare mitochondrial disorders.  Testing of 
POLG and common mtDNA mutations (m.3243A>G associated with MELAS and 
maternally inherited diabetes and deafness [MIDD], m.8344A>G associated with myoclonic 
epilepsy with ragged red fibres [MERRF], and m.8993T>G/C associated with Leigh 
syndrome and neurogenic muscle weakness ataxia and retinitis pigmentosa [NARP]) in DNA 
extracted from blood was available through the highly specialised service laboratories.  
Further testing (such as gene panel testing) was available after discussion with the highly 
specialised services depending on the patient’s clinical features (Supplementary Table 1).  
 
Clinical Information 
The referring clinician provided clinical information against a standardised list of clinical 
features as yes/no answers (Supplementary Table 2), or using a standardised vocabulary for 
describing clinical features encountered in human disease (the Human Phenotype Ontology, 
HPO23).   HPO classifies clinical features by organ system using a branching tree 
incorporating increasing levels of detail.  We used modified HPO terms to score participants 
using the Nijmegen Mitochondrial Disease Criteria (NMDC)24,25(Supplementary Table 3), 
which uses clinical features (muscular, central nervous system and multi-system), MRI and 
biochemical features, and muscle biopsy results to give a score out of 12.  Patients with a 
total of 0-1 were classified as being unlikely to have a mitochondrial disorder; score 2-4 a 
possible mitochondrial disorder; score 5-7 a probable mitochondrial disorder; and score 8 or 
more as definite mitochondrial disorder.  One investigator scored all the participants.  100 
participants were also scored independently by a second investigator to develop the 
modifications for using the NMDC with HPO terms.  For each HPO term, the HPO system 
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was determined by following the branching tree back to the subtype of ‘Phenotypic 
abnormality’. 
 
Whole Genome Sequencing 
DNA extraction from peripheral blood, quantification, and sequencing was performed 
according to a national specification (Illumina TruSeq, HiSeq 2500 and HiSeq X)26,27 with 
reads aligned to the Genome Reference Consortium human genome build 37 (GRCh37) for 
the earlier participants recruited, and GRCh38 for later participants using Isaac Genome 
alignment software.  Family based variant calling of single nucleotide variants and insertion 
deletions for chromosomes 1-22, X and the mtDNA was performed using the Platypus 
variant caller28 allowing joint variant calling for all family members and considering the 
sequence alignments from all family members together. 
 
The analysis workflow is shown in Figure 1. 
 
Nuclear variant analysis – single nucleotide variants and small insertion-deletion variants 
(indels) 
Genomes were analysed in families and variants were classified into four ‘Tier’ groups 
according to the probability of the variant being causative21. Tier 1 included loss of function 
variants (nonsense variants, essential splice donor and essential splice acceptor variants) and 
de novo missense or splice region variants in genes on the panels applied; Tier 2 included 
missense and splice region variants in genes on the panels applied; Tier 3 included other rare 
variants; and a final group of unclassified variants had higher population frequency or the 
segregation pattern in the family was not consistent with the family history. Virtual gene 
panels were chosen according to each participant’s phenotypes, using curated ‘PanelApp’ 
gene lists, which include causative genes for each disorder generated through 
crowdsourcing29. This allowed the prioritisation of variants likely to be causative and  
minimised the reporting of abnormal genetic results which are unrelated to the reason for 
testing, for example cancer predisposition genes (referred to as incidental findings). All 
participants had the mitochondrial panel applied, and further panels depended on the 
phenotypes. Tier 1-3 variants were accessed from the Main Programme v8_2019-11-28. All 
Tiered variants had passed in-house Genomics England quality control30. Variants were also 
prioritised by Exomiser31, an application which prioritises variants in exome or genome data 
using protein interaction networks, clinical relevance and cross-species phenotype 
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comparisons as well as computational filters for variant frequency, predicted pathogenicity 
and pedigree information.  Variants classified as Pathogenic, Likely Pathogenic or 
Pathogenic/Likely Pathogenic were extracted from Clinvar32 (3.3.2020) for GRCh38 and 
GRCh37 and compared against Tier 1-3 variants using bedtools intersect 
(https://bedtools.readthedocs.io) in order to identify previously reported pathogenic and likely 
pathogenic variants.  
Gene panels applied 
The Mitochondrial Disorders panel was applied in all participants.  Other panels applied 
included Undiagnosed Metabolic Disorders (148 participants), Intellectual Disability (139), 
Congenital Myopathy (77), Hereditary Ataxia (60)(see Supplementary Table 4).  The mean 
number of panels applied per participant was 4.7 (range 1 to 18). A total of 93 different 
panels were applied to between 1 and 345 participants.  
 
Nuclear variant analysis – copy number variants 
Copy number variant (CNV) calls were detected using Canvas software33 based on sequence 
coverage and both nucleotide and Indel variant calling.  We only included CNV calls with 
PASS filter status assigned by Canvas and overlapped any gene in PanelApp.  CNV calls 
were annotated using gencode v29. CNVs which interrupted exons of a PanelApp gene were 
evaluated.  All the CNVs reported as a diagnosis were manually confirmed on Integrative 
Genomics Viewer (IGV).   
 
Nuclear variant analysis – short tandem repeat expansions 
Short tandem repeat expansion genotyping was performed using the 
ExpansionHunter version 3.2.2 software package34.  Thirteen loci were assessed (HTT, AR, 
ATN1, ATXN1, ATXN2, ATXN3, ATXN7, CACNA1A, TBP, C9orf72, 
FXN, FMR1 and DMPK) using the coordinates listed in Supplementary Table 5.  Potentially 
causative repeat expansions above an established threshold for each locus (Supplementary 
Table 6) were visually inspected using pileup plots and re-classified based on the quality of 
the reads34. 
 
mtDNA variant analysis 
An in-house pipeline was used to call mtDNA single nucleotide variants above an established 
detection threshold of >1% variant allele frequency (VAF, or percentage heteroplasmy 
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level)35 after excluding likely errors27.  These were compared to a manually curated list of 
pathogenic mutations with functional evidence supporting pathogenicity36.  Our pipeline does 
not detect large scale mtDNA rearrangements which usually require targeted mtDNA 
analysis in DNA extracted from skeletal muscle. 
 
Clinical Review – Single nucleotide variants and small insertion-deletion variants (indels) 
Tier 1 and Tier 2 variants, the top ten prioritised variants by Exomiser, ClinVar 
pathogenic/likely pathogenic variants and the mtDNA variants (tier 1-3 and from the in-
house pipeline) were reviewed by a Clinical Geneticist and classified using internationally 
accepted criteria for pathogenic variants, likely pathogenic variants, variants of uncertain 
clinical significance, and likely benign or benign variants (American College of Medical 
Genetics [ACMG] criteria37), incorporating information from gnomAD38, ensembl39, 
VarSome40, OMIM and a review of the literature (a description of the online resources used 
is in the Supplementary Methods). Variant quality and variant allele frequency were checked 
using IGV41.  
 
Clinical Review – Copy Number Variants 
CNVs which overlapped at least one exon in a PanelApp gene were reviewed in DECIPHER.  
Information about the type of variant (copy number loss, copy number gain or loss of 
heterozygosity), the size of the variant and the gene content (in particular, haploinsufficient 
genes and OMIM morbid genes) was reviewed.  A comparison was also made with 
previously observed CNVs in the general population or in affected individuals.   
 
Clinical Review – Short tandem repeat expansions 
Participants with repeat expansions were reviewed to see whether they were causative, 
considering the size of the expansion (whether it was a ‘pre-mutation’ or ‘full mutation’) and 
the participant’s age and phenotypic features. 
 
Feedback from Genomic Medicine Centre laboratories and clinical teams 
The Genomic Medicine Centre laboratories were commissioned to analyse the Tier 1 and 
Tier 2 variants.  They filled out an ‘exit questionnaire’ for each family through an online 
questionnaire.  For each family, they fed back whether genetic cause had been identified with 
options of ‘solved’, ‘partial’, ‘uncertain’ or ‘no’ and whether the result was already known 
through clinical testing.   For variants which the clinical scientists had identified as 
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potentially causative, they fed back their variant classification according the ACMG criteria 
and whether or not the variant had been confirmed by Sanger sequencing and fed back to the 
clinician.  Feedback from the GMC laboratories was available in 277/319 (87%) families 
(data release v12_21_05_06).  We successfully contacted clinicians for further information in 
55 (17%) families. 
 
Overall clinical assessment  
The molecular diagnosis was described as ‘definite’, ‘probable’, or ‘possible’ based on our 
overall clinical assessment of whether the variant(s) explained the clinical features, taking 
into account the ACMG classification of the variant(s), the inheritance pattern and the 
clinical fit between the patient’s HPO terms and the reported clinical phenotypes for the gene 
or variant. For example, we used ‘probable’ for compound heterozygotes where the 
phenotype fitted with the disorder but only one variant was classified as pathogenic/likely 
pathogenic and the other was a variant of uncertain clinical significance.  The contribution 
was described as ‘full’ or ‘partial’ depending on whether the whole phenotype or only one 
aspect could be explained by the variant(s). Nuclear genes were classified as ‘mitochondrial’ 
based on the curated PanelApp list29, plus recently discovered genes known to have a direct 
effect on oxidative phosphorylation.    
 
Statistical Methods 
Statistical analyses were performed in R.  Fisher’s exact test was used to compare the number 
of participants with a genetic diagnosis in children and adults, and in singletons compared to 
trios/quads.  The mean number of HPO terms in diagnosed and undiagnosed individuals was 
compared using students t-test, and similarly for the number of HPO systems affected.  
Fisher’s exact test was used to compare the proportion of families with each inheritance 
pattern between nuclear-mitochondrial diagnoses and non-mitochondrial disorders.  The 
proportion of participants with each HPO system affected was compared between participants 
with definite mitochondrial diagnoses and definite non-mitochondrial diagnoses, using 
Fisher’s exact test.  The mean Mitochondrial Diagnostic Criteria score was compared 
between participants with mitochondrial diagnoses, non-mitochondrial diagnoses and 
undiagnosed participants using a One-way ANOVA and post-hoc Tukey testing.    
Patient and Public Involvement 
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The 100, 000 Genomes Project has a Participant Panel made up of participants and parents or 
carers of people involved in the project which was established in 2016.  The Panel meets with 
senior staff from Genomics England and NHS England four times a year.  They are asked 
about project design and help ensure that participants’ health data is looked after with respect 
and used in the best interests of the participants. Panel members sit on other committees 
including the Access Review Committee and the Ethics Advisory Committee. Patients and 
carers were involved in developing the consent literature and the infographics and 




345 affected individuals (186 females, 159 males) were referred with a suspected 
mitochondrial disorder after excluding common causes. These were from 319 families of 
different reported ethnicities across England (Figure 2). Genomic data were available for 
more than one affected member in 25 families (15 sibling pairs, eight mother and child pairs, 
one father and child pair, and one mother with two affected children). The median age at 
enrolment for probands was 25 years (IQR 10-54, range 0 to 92 years). 143 (41%) were aged 
<=18 at enrolment.  No participants withdrew or were lost to follow up. 
 
Phenotype data  
Phenotypic data was available for 341 participants (missing in 4 participants).  3095 HPO 
terms were recorded, with a median of 7 HPO terms per participant (range 1 to 39).  806 
different HPO terms were used.   The commonest clinical terms, investigation result terms 
and HPO systems affected are shown in Figure 2d-f. A median of 4 HPO systems were 
affected per participant (range 1 to 13). Application of the HPO-modified Nijmegen score 
gave a mean total score of 4.30 (range 0-10), with 24 participants (7%) classified as being 
unlikely to have mitochondrial disease (score 0 or 1), 193 (56%) ‘Nijmegen possible’ (score 
2-4), 95 (27.5%) ‘Nijmegen probable’ (score 5-7) and 33 (9.5%) ‘Nijmegen definite’ with a 




The definite or probable genetic diagnosis was identified in 31% of families with a possible 
diagnosis in an additional 2% (Table 1, Figure 1, Figure 3a). A definite genetic diagnosis was 
reached in 28% (89/319) including 14 genetic diagnosis (4%) which provided only a partial 
explanation for their clinical features.  Nine participants (3%) had a probable diagnosis and 
six (2%) had a possible diagnosis.  One participant was diagnosed with two disorders which 
together fully explained their combination of phenotypes.  The majority of diagnoses 69/104 
(66%) came from single nucleotide variants (SNVs) or INDELs on the panels applied (Tier 1 
or Tier 2 variants).  An additional 19/104 (18%) diagnoses were made through other analyses 
of the SNVs and INDELS (from the GMC laboratory reports, comparison to ClinVar and 
Exomiser).  The copy number variant analysis added 8 diagnoses (8%) and the short tandem 
repeat analysis added three diagnoses (3%).  Five diagnoses were made through the mtDNA 
analysis (5%).  Further details of the variant analysis are show in Supplementary Table 7. 
Factors affecting diagnostic yield 
The overall diagnostic rate was 59/186 (32%) in females and 51/159 (32%) in males. 64/143 
(45%) participants recruited aged 18 or under received a diagnosis (any type), compared to 
46/202 (23%) participants over the age of 18 (p<0.001).  Considering definite diagnoses only, 
50/143 (35%) participants under 18 received a definite molecular diagnosis compared to 
30/202 (15%) adults over the age of 18 (p<0.001). Figure 3b shows the age profile for 
diagnosis. Although diagnoses were more frequent in younger people, diagnoses were still 
being made in participants who were in their 70s or 80s at enrolment. 
The diagnostic yield per family (all diagnoses) was 23% for singletons (23/102), 29% (12/42) 
for duos with a parent, 42% (62/148) for trios/quads and 26% (7/27) for other family 
structures. The diagnostic rate in trios/quads was higher than in singletons (p=0.005). The 
mean age of singletons was 56 years, compared to a mean age of 12 years for probands in 
trios/quads. 
The mean number of HPOs in participants with any diagnosis (10.0) was slightly higher than 
in undiagnosed patients (8.48) (p=0.030).  The mean number of HPO systems affected in 
diagnosed patients (4.67) was not significantly different from the mean number of HPO 
systems affected in undiagnosed patients (4.61) (p=0.82). 
Types of Diagnosis 
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Of the families with a definite diagnosis which fully explains the phenotype, 28 were in 
genes known to cause primary mitochondrial disease (37%) including four mtDNA variants 
and 24 diagnoses in nuclear-mitochondrial genes, whereas 47 were in non-mitochondrial 
genes (63%). For families with any genetic diagnosis (including probable or possible 
diagnoses and partial explanations), 39 were in genes known to cause primary mitochondrial 
disease (37.5%) including six mtDNA variants and 30 nuclear-mitochondrial diagnoses, and 
65 were in non-mitochondrial genes (62.5%). These non-mitochondrial disorders included a 
wide variety of disorders, including developmental disorders with intellectual disability, 
metabolic disorders, epileptic encephalopathies, Bardet-Biedl syndrome, cardiomyopathies, 
MYH2-related myopathy and amyloidosis.   
Potentially Treatable Disorders 
There were potentially treatable disorders identified in six participants with a mitochondrial 
disorder and nine participants with a non-mitochondrial disorder (shown in Supplementary 
Table 8).  However, it should be noted that the evidence base is weak for several of these rare 
disorders42. 
Mitochondrial Diagnoses compared to Non-Mitochondrial Diagnoses 
Inheritance Patterns: 70% (23/33) of families with a nuclear-mitochondrial diagnosis 
showed an autosomal recessive inheritance pattern, compared to 35% (23/65) of families with 
non-mitochondrial disorders. Five families (15%) had de novo diagnostic variants in nuclear-
mitochondrial genes (AIFM1, LONP1 and PDHA1 and two with de novo duplications in the 
ATAD3 gene cluster) compared to 29% (19/65) of families with non-mitochondrial disorders 
having a de novo diagnosis (Figure 3c), particularly those with intellectual disability or 
epileptic encephalopathy.  The HK1 variant was de novo in two siblings with presumed 
germline mosaicism (somatic mosaicism was not detected in either parent).  The proportions 
with each inheritance pattern were significantly different between nuclear-mitochondrial 
diagnoses and non-mitochondrial disorders (p=0.007). 
HPO Systems affected:  In our cohort, participants with a mitochondrial diagnosis were more 
likely to have HPO-terms in the Metabolism/Homeostasis system (p<0.001) such as 
increased lactate or decreased mitochondrial complex activities, compared to those with non-
mitochondrial diagnoses (Figure 4).  
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Modified Nijmegen Mitochondrial Disease Criteria scores: The majority (22/30, 73%) of 
participants with genetically confirmed mitochondrial diagnoses (nuclear-mitochondrial and 
mtDNA) had scores in the Nijmegen probable (5-7) and Nijmegen definite (8-12) modified 
Nijmegen MDC category (Figure 3d), whereas 60% (30/50) of participants with confirmed 
non-mitochondrial disorders had scores in the Nijmegen possible range (2-4). The mean 
MDC score differed between diagnostic groups (p<0.001), including between the 
mitochondrial diagnoses and the non-mitochondrial diagnoses (p<0.001), and between the 
mitochondrial diagnoses and patients with no diagnosis (p<0.001), but not for the non-
mitochondrial diagnoses and undiagnosed patients (p=0.36).  However, 16 of the 50 (32%) 
participants with confirmed non-mitochondrial disorders had scores in the ‘Nijmegen 
probable’ range, and 3 (6%) in the ‘Nijmegen definite’ range. The sensitivity and specificity 
of the MDC score in our cohort is shown in Supplementary Table 9.  Using ‘Nijmegen 
definite’, the MDC score was highly specific but sensitivity was only 40%, whereas using a 
‘Nijmegen probable and definite’ scores, the score was moderately sensitive and moderately 
specific.   
Muscle biopsy findings and mitochondrial complex activities 
117 participants (34%) had HPO terms relating to muscle biopsy abnormalities, and 73 (21%) 
had abnormal mitochondrial complex activities.  In patients with definite mitochondrial 
diagnoses, 15/28 (54%) had muscle biopsy abnormalities, 11/28 (39%) had abnormal 
respiratory chain complex activities and two had abnormal PDH complex activity.  In 
patients with definite non-mitochondrial diagnoses, 14/47 (30%) had muscle biopsy 
abnormalities and 12/47 (26%) had abnormal respiratory chain complex activities.   The 
patients with non-mitochondrial diagnoses and abnormal respiratory chain complex activities 
had pathogenic variants in ASXL3, CACNA1E, CTBP1, EXOSC3, HK1, KCNT1, NPHP1, 
P4HTM, PPP2R5D and SCN2A, SOS1 and TANGO2.    
Discussion 
In patients referred for WGS with a suspected mitochondrial disorder, a definite or probable 
diagnosis was identified in 31% (including partial diagnosis in 4%) and a further 2% had a 
possible diagnosis.  The mitochondrial diagnoses were nearly all unique to one family, 
reflecting the high level of genetic heterogeneity in mitochondrial disorders.  Non-
mitochondrial disorders were more common than mitochondrial disorders and had features 
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resembling mitochondrial diseases (often referred to as ‘phenocopies’).  These could be 
broadly classified as developmental disorders with intellectual disability, metabolic disorders, 
myopathies, cardiomyopathies, epileptic encephalopathies, leukodystrophies, ciliopathies, 
amyloidosis, and other neurogenetic disorders, including basal ganglia calcification and 
neurodegeneration with iron accumulation.  29% of the non-mitochondrial disorders were 
caused by de novo pathogenic variants.    
 
The diagnostic yield was significantly greater in children than adults.  There are several 
possible explanations for this.   First, children were more likely to be recruited as trios with 
both parents. This makes analysis more straightforward43 because de novo variants can be 
identified, rare familial variants can be filtered out if the parents are clinically unaffected for 
recessive disorders, and it can be checked that the variants were inherited from both parents.  
Second, the most severe phenotypes are seen in children because affected individuals do not 
survive until adulthood44.  Severe phenotypes are the most likely to be caused by single gene 
disorders. Milder phenotypes overlap with acquired disorders, are less likely to be caused by 
a single gene defect, and are more common in adults.  Third, most adults with genetically 
proven mitochondrial disorders have a mutation in the mtDNA which were excluded by the 
clinical laboratories before inclusion in this study.  Studies of whole exome sequencing in 
rare disease have also noted a decrease in diagnostic yield with an increasing age of the 
probands45.  Despite this, in our study, new genetic diagnoses were made across the whole 
age spectrum.  The oldest patient to receive a genetic diagnosis was recruited at age 86.    
 
There was also variability in the number of people recruited in different age groups.  The 
highest numbers were recruited in the paediatric age group, with a second peak of patients 
aged over 60 years.  This could be because  some adult-onset mitochondrial disorders, such 
as progressive external ophthalmoplegia (CPEO), take time to develop and only become 
obvious in later life (CPEO was present in 17/71(24%) in over 60s compared to 16/274 (6%) 
in under 60s). Alternatively, this could reflect the fact that genetic testing had not have been 
offered previously to the older individuals due to the financial cost and perceived lack of 
immediate management implications.  The 30-39 years age group were the least likely to be 
recruited and had a low diagnostic rate.  A common reason for seeking a clinical genetics 
referral is for reproductive advice, so we speculate that this age group are more likely to have 
been reviewed by a clinical geneticist and offered up to date genetic testing (such as panel 
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testing) in a clinical setting, meaning that there were fewer undiagnosed patients and that the 
remaining ones were more difficult to diagnose. 
 
It is possible that the relatively high frequency of partial diagnoses in this study (4%) reflects 
our current knowledge of the phenotypic spectrum of ultra-rare genetic diseases, and that 
some of the features we have not ascribed to the causal variants are actually due to the 
underlying mutations. This is likely to be a particular problem for mitochondrial disorders 
because of their diverse phenotypes, some of which are only just being recognised36, but will 
become easier as our knowledge base increases.   
 
Strengths and weaknesses of the study in relation to other studies 
Our study had several strengths, including the large sample size, and the fact that patients 
were recruited nationally from both secondary and tertiary care, meaning that the findings 
have a wider relevance than studies focussed on highly selected groups identified by 
specialist centres. In addition, the use of HPO terms allowed phenotype data to be analysed in 
a systematic way, and we contacted clinicians for detailed phenotypic information in selected 
participants.  Our analysis of the nuclear genes included copy number variants and short 
tandem repeat expansions in addition to single nucleotide variants and small indels; and we 
also studied mtDNA variants with a heteroplasmy level >1%.  The advantage of using WGS 
rather than WES was that it is easier to pick up CNVs, repeat expansions and lower level 
heteroplasmies.  Weaknesses are that we have not explored novel disease genes or variants in 
the non-coding regions, other than  previously published variants, and it was not possible to 
trace all family members. 
 
The previously published study using whole genome sequencing in patients with suspected 
mitochondrial disease19 looked at a cohort of 40 children recruited from four paediatric 
genetic metabolic centres in Australia.  34/40 had a ‘probable’ or ‘definite’ mitochondrial 
disorder using the modified Nijmegen mitochondrial disease criteria score (between 5 and 
12) and 28 had abnormal respiratory chain enzyme activities. Analysing nuclear and mtDNA 
enabled a definitive genetic diagnosis for 55% of patients, and a likely molecular diagnosis in 
67%, with 17.5% having a non-mitochondrial disorder.  The higher diagnostic yield in this 
study19 likely reflects the section criteria which focussed on children within trios identified by 
national specialist clinics, compared to our more inclusive recruitment criteria where ~2/3 of 
our probands were adults, and only 46% of families were recruited as trios. 
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A number of studies using whole exome sequencing in patients with suspected mitochondrial 
disorders have been reviewed recently46. Most studies of these studies were conducted in 
highly selected patients seen in specialist centres10,12,16, focussing on childhood-onset 
disorders (apart from Ref 14 which included patients up to 27 years of age). Their stringent 
recruitment criteria led to higher diagnostic yields (57-68%) and lower number of non-
mitochondrial diagnoses in comparison with our study. Previous exome studies of larger 
cohorts14,15 have also tended to have a lower diagnostic yield (34.5- 39%) which is thought to 
be more reflective of everyday clinical practice46.  Non-mitochondrial disorders have been 
found in some of the previous studies, but in much smaller numbers compared to this study.  
The recruitment criteria in our study were broad, which is reflective of mainstreaming of 
genomic medicine and we studied both adults and children.  Most participants (64%) did not 
have muscle biopsy results available at the time of referral, whereas most participants in 
previous studies had evidence of mitochondrial dysfunction.  The more inclusive eligibility 
criteria have led to finding a wide range of different genetic diagnoses.  The finding that a 
large number of patients had non-mitochondrial disorders is important because these 
diagnoses would have been missed if the participants had been investigated only for 
mitochondrial disorders through muscle biopsy and/or a specific mitochondrial gene panel.  
This would have led to missed opportunities for treatment, surveillance and reproductive 
management.  Our findings highlight the difficulty of diagnosing these rare multisystem 
disorders clinically and the need to keep an open mind about the differential diagnosis. 
 
Considering other studies of integration of whole genome sequencing into healthcare, 
Stranneheim et al47 describe the results for 3219 rare disease patients recruited in Stockholm, 
Sweden between 2015 and 2019.  Their study involved much more direct collaboration 
between academia, healthcare and their SciLifeLab (which provides WGS), which were all 
located in the same city.  This meant that potential diagnoses were discussed and specialist 
advice was fed back quickly into clinical practice.  Specialist clinicians could also access and 
analyse the data together with clinical scientists.   The 100,000 genomes project used a 
different model with the bioinformatics managed centrally and the clinical interpretation of 
variants done by Genomic Medicine Centre laboratories.  Researchers were able to access 
pseudonymised data.  The limited ability researchers and clinicians to discuss potential 




Unanswered questions and future research   
The participants in this study had standard of care NHS genetic testing prior to enrolment.   
The use of WGS as a first genetic test for suspected mitochondrial disorders has not been 
directly explored.  The only mitochondrial diseases which cannot be diagnosed by WGS of 
DNA extracted from blood are extremely rare muscle specific mtDNA mutations and large 
mtDNA deletions which usually have usually a very specific clinical phenotype.  Based on 
known epidemiology1,50, these muscle specific mtDNA mutations and deletions account for 
~11.5% of genetically confirmed mitochondrial disorder patients.  Therefore nearly 90% of 
mitochondrial disorder patients can be diagnosed by WGS of DNA extracted from blood51.  
Additionally, WGS can diagnose other monogenic disorders which have similar clinical 
features, so we would expect a very high diagnostic yield.  Finally, by carrying out this study 
we have identified a cohort of patients with suspected mitochondrial disease where the likely 
diagnosis is contained within the WGS sequence data, but cannot be distinguished from 
background sequence variation. This will form a useful resource for the discovery of future 
mitochondrial disease genes that are not in the coding space, and thus are not detectable by 
WES.  Large scale mtDNA rearrangements are not currently reliably detected in DNA 
extracted from blood in adults, meaning that patients with suspected CPEO and Kearns-Sayre 
syndrome are investigated by muscle biopsy20.  Future research will determine whether deep 
mtDNA sequencing will detect these large scale mtDNA rearrangements in DNA extracted 
from blood or another accessible tissue such as urinary epithelium. 
 
Policy implications 
Our findings indicate that whole genome sequencing is a useful diagnostic test in patients 
with suspected mitochondrial disorders recruited from secondary and tertiary care settings.  
We recommend that whole genome sequencing should be offered early in the diagnostic 
pathway in a patient’s local secondary or tertiary care centre, and before invasive tests such 
as a muscle biopsy.  Exceptions to this would be patients whose clinical features are highly 
suggestive of a specific cause which can be confirmed by a single gene test or common 
mtDNA mutation testing, and also patients with progressive external ophthalmoplegia which 
is currently diagnosed in most patients by testing mtDNA from a muscle biopsy sample for a 
large-scale rearrangements. Referral to a specialised mitochondrial clinic should be arranged 
if a mitochondrial diagnosis is confirmed, or for further investigations if WGS sequencing is 
uninformative. Further investigations likely to increase the diagnostic yield beyond WGS 
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include laboratory studies of mitochondrial function and other ‘omics’ approaches including 
transcriptomics, which provided an additional diagnosis in 10% of suspected mitochondrial 
disease patients in one study48, proteomics, and metabolomics.  
 
There are also wider policy implications for the integration of whole genome sequencing into 
healthcare.  The relatively high number of patients with probable or possible diagnoses partly 
reflects the current lack of capacity for the functional evaluation of variants of uncertain 
clinical significance, for example through splicing assays or Western blotting.  Resources 
should also be made available for the regular re-analysis of WGS data, either at specified 
time intervals in undiagnosed patients or on clinician request. The re-analysis of exome data 
has been shown to significantly increase diagnostic yield, mainly due to newly discovered 
disease genes49. Finally, rapid trio whole genome sequencing17 should be offered in acutely 
unwell individuals with suspected mitochondrial disorders, so that the results can help guide 
clinical management.  In the UK, rapid trio exome sequencing is currently available for 
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Tables & Figures  
 
Table 1. Variants identified in patients with definite, probable and possible diagnoses.  
Genetic diagnoses made in 104 families, including age and sex of participants, contribution to 
the phenotype from this gene (full or partial), gene, variants, ACMG variant classification 
(P=Pathogenic, LP=Likely Pathogenic, VUS= Variant of Uncertain Clinical Significance) 
and inheritance pattern.  (A) Variants in mitochondrial genes are shown in the upper panel 
and (B) those in non-mitochondrial genes are shown in the lower panel table. Novel variants 
are indicated with # and five previously published families are also indicated with $.  For 
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family 84, the full phenotype is explained by the two genetic diagnoses.  In family 77, the 
NPHP1 homozygous deletion explains the phenotype in the sibling with a severe phenotype 
(with childhood onset end stage renal disease) and is heterozygous in the other sibling. 
 










1 10 F Full AARS2 NM_020745.4:c.302G>A p.(Arg101His) 
Homozygous 
LP Biallelic 
2 1 M Full AIFM1 NM_004208.4: c.603_605del p.(Arg201del) P XLR 
de novo 
3 0 F Full ATAD3 Duplication in ATAD3 gene cluster P Monoallelic 
de novo 
4 0 M Full ATAD3 Duplication in ATAD3 gene cluster P Monoallelic 
de novo 






6 6 M Full EARS2 
 




7 2 F Full FBXL4 NM_001278716.2:c.1641_1642delTG 
p.(Cys547Ter) 





8 18 F Full HIBCH NM_014362.4:c.1126T>G p.(Phe376Val) # 
Homozygous 
LP Biallelic 
9 22 F Full KARS1 NM_001130089.1:c.683C>T p.(Pro228Leu) 




10 1 F Full MRPL44 NM_022915.4:c.467T>G p.(Leu156Arg) 
Homozygous 
P Biallelic 





12 42 F Full MT-ATP6 m.8618dupT 
14% heteroplasmy 
P mtDNA 
very low level 
in mother 






















18 10 F Full MTO1 NM_012123.4:c.1232C>T p.(Thr411Ile) 
Homozygous 
P Biallelic 
19 13 F Full NDUFAF5 NM_024120.5:c.480-3T>G# 





























Full PDP1 NM_018444.4:c.571C>T p.(Gln191Ter) # 
Homozygous 
LP Biallelic 







Full RRM2B NM_001172477.1:c.242G>A p.(Asp142Asn) P Monoallelic 
(AD) 






27 0 F Full SCO2 NM_001169109.1:c.323A>G p.(Asp108Gly) # 




28 74 F Full SLC25A4 NM_002252.4:c.311A>G p.(Asp104Gly) P Monoallelic 
(unknown) 







30 66 M Full TWNK NM_021830.5:c.1374G>T p.(Gln458His) P Monoallelic 
(unknown) 
Probable 




32 4 F Full ELAC2 NM_018127.7:c.2009delG p.(Cys670fs) 





















36 3 M Full SDHA NM_004168.4:c.290G>C p.(Arg97Thr) # 





37 18 M Full LONP1 NM_004793.4: c.1694A>G p.(Tyr565Cys) VUS De novo 
38 0 M Full PDHA1 NM_000284.4: c.759+5G>T 
 







Full TOP3A NM_004618.5:c.284C>T p.(Ala95Val) # 





















40 0 F Full ACTA2 NM_001614.4:c.536G>A p.(Arg179His) P Monoallelic 
de novo 
41 42 F Full AMACR NM_014324.6:c.857delT p.(Ile286fs) # 




42 57 M Full AMACR NM_014324.6:c.154T>C p.(Ser52Pro) 
Homozygous 
P Biallelic 
43 71 F Full AMACR NM_014324.6:c.154T>C p.(Ser52Pro) 
Homozygous 
P Biallelic 








Full APP NM_000484.4:c.2075C>G p.(Ala692Gly) P Monoallelic 
AD 
46 18 M Partial ASL NM_000048.4:c.1153C>T p.(Arg385Cys) 
Homozygous 
P Biallelic 
47 15 M Full ASXL3 NM_030632.3:c.3464c>A p.(Ser1155Ter) P Monoallelic 
de novo 
48 15 M Full ATP1A3 NM_152296.5:c.2452G>A p.(Glu818Lys) P Monoallelic 
de novo 
49 86 F Full ATP1A3 NM_152296.5:c.2452G>A p.(Glu818Lys) P Monoallelic 
Unknown 
50 5 M Full ATP6V1A NM_001690.4:c.845A>T p.(Asn282Ile) # LP Monoallelic 
de novo 
51 1 F Full ATXN7 $ Very large CAG repeat expansion P Monoallelic 
52 44 F Full BBS1 NM_024649.5:c.1169T>G p.(Met390Arg) 
Homozygous 
P Biallelic 
53 2 M Full BCAP31 NM_001256447.2:c.565C>T p.(Gly189Ter) # P XLR 
de novo 
54 26 F Full C19orf12 NM_001256047.1:c.245dupC p.(Ala83fs) # LP Monoallelic 
unknown 




56 2 M Full CACNA1E NM_001205293.3:c.683T>C p.(Leu228Pro) LP Monoallelic 
de novo 














59 12 F Full DSP NM_004415.4:c.1799T>C p.(Phe600Ser) # LP Monoallelic 
de novo 
60 8 F Full EXOSC3 NM_016042.4:c.395A>C p.(Asp132Ala) 
Homozygous 
P Biallelic 
61 61 M Partial EYA4 NM_004100.5:c.1741A>T p.(Lys581Ter) # LP Monoallelic 
Unknown 
62 2 M Full FIG4 NM_014845.6:c.447-2A>G# 




63 6 F Full GCDH NM_000159.4:c.1204C>T p.(Arg402Trp) 




64 3 F Full HADHA NM_000182.5:c.1528G>C p.(Glu510Gln) 




65 10 F Full HK1 NM_000188.3:c.1334C>T p.(Ser445Leu) P Monoallelic 
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8 F de novo 
66 9 M Full HSD17B4 NM_000414.4:c.590_597dupGATCACGG 
p.(Met200fs)* 





67 71 M Partial HTT $ ~40 CAG repeats P Monoallelic 
68 7 F Full HTT $ Very large CAG repeat expansion P Monoallelic 
69 41 M Partial KCNQ4 NM_004700.4:c.961G>A p.(Gly321Ser) P Monoallelic 
unknown 
70 6 F Full KCNT1 NM_020822.3:c.1885A>c p.(Lys629Gln) LP Monoallelic 
de novo 
71 46 F Full KIF11 NM_004523.4:c.78-2A>G# P Monoallelic 
AD 




73 0 F Full MBD5 NM_001378120.1 deletion of exon 2 LP Monoallelic 
unknown 
74 72 M Full MYH2 NM_017534.6:c.2116G>A p.(Glu706Lys) P Monallelic 
unknown 
75 57 M Partial MYH7 NM_000257.4:c.1357C>T p.(Arg453Cys) P Monoallelic 
unknown 




F, F Full NPHP1 Gene deletion  
Homozygous 
P Biallelic 
78 3 M Full NPHP1 Gene deletion 
Homozygous 
P Biallelic 
79 31 F Partial OPTN Gene deletion P Monoallelic 
unknown 
80 1 M Full P4HTM NM_177939.3:c.659G>A p.(Trp220Ter) # 




81 36 F Full PDGFB Gene deletion P Monoallelic 
AD 





83 3 M Partial PKD2 NM_000297.4:c.1390C>T p.(Arg464Ter) P Monoallelic 
AD 




NM_000303.3:c.305A>G p.(Tyr102Cys) # 
NM_000486.6:c.707_720dupTGCTGAAGG
GCCTG p.(Glu241fs) # 









85 2 F Full POGZ NM_05100.4:c.2571-2delA# P Monoallelic 
de novo 









88 7 F Full SAMD9 NM_001193307.1: c.2053C>T p.(Arg685Ter) LP Monoallelic 
de novo 




90 49 F Full SHOC2 NM_007373.4:c.519G>A p.(Met173Ile) LP Monoallelic 
unknown 
91 56 M Partial SLC20A2 NM_001257180.2:c.852delC p.(Ile1285fs) # LP Monoallelic 
unknown 






93 11 F Full SOS1 NM_005633.3.3:c.1294T>C p.(Trp432Arg) P Monoallelic 
de novo 
94 12 M Partial TAB2 NM_001292034.3: c.-90+1G>C LP Monoallelic 
de novo 
95 7 F Full TANGO2 Deletion exons 3-9 
Homozygous 
P Biallelic 




97 73 M Full TTR  NM_000371.3:c.407A>C p.(Tyr136Ser) P Monoallelic 
unknown 





99 59 F Full CTNNB1 NM_001904.4:c.2315delA p.(Asn772fs) # LP Monoallelic 
Unknown 
100 0 M Full MYBPC3 NM_000256.3:c.1357_158delCC p.(Pro453fs) 












103 52 M Full MYH2 
 
 
NM_017534.6:c.2387C>A p.(Ala796Asp) # VUS Monoallelic 
unknown 
104 13 M Full MYO9A NM_006901.4:c.6796A>T p.(Asn2266Tyr) # 






Figure 1.  Overview of the analyses performed and sources of diagnoses.  Variants in nuclear genes were analysed using the Genomics 
England tiering system.  All tier 1 and tier 2 variants were reviewed and these provided 66% of the diagnoses.  A further 19.5% of diagnoses 
were based on feedback from the Genomic Medicine Centre (GMC) labs, comparison to Clinvar pathogenic and likely pathogenic variants, and a 
review of the top ten Exomiser prioritised variants. mtDNA variants were analysed separately using an in-house pipeline and comparison against 
a list of 89 pathogenic variants, yielding and extra 5 diagnoses (6%).  Copy number variants accounted for 8% of diagnoses, and short tandem 
repeat expansions for 3%. 
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Figure 2. Demographics and Human Phenotype Ontology terms for the participants recruited.  (a) Ethnicities recorded in the participants 
reflected the ethnicity of the overall population in England.  (b) The most commonly recruited family structures were trios with both parents and 
singletons.  (c) Genomic Medicine Centres. Participants were recruited from Genomic Medicine Centres across England. (d) Clinical HPO 
terms. The most commonly recorded clinical HPO terms including delayed gross motor development, intellectual disability and myopathy. (e) 
Investigation HPO terms.  The most commonly recorded investigation results HPO terms including decreased activity of mitochondrial complex 
IV, lactic acidosis and decreased activity of mitochondrial complex I. (f) HPO Systems.  The total number of HPO terms recorded for the 345 
participants according to the ancestor HPO system.  (Note that some HPO terms have more than one ancestor HPO system.)  
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Figure 3. Clinical features in patients with different types of diagnoses. (a) Overview of proportion of patients diagnosed. (b) Age 
distribution of the participants at the time of enrolment and the type of diagnoses made.  The diagnostic yield was higher in younger participants, 
but diagnoses were still being made in patients enrolled in their 70s and 80s. (c) Inheritance patterns in nuclear mitochondrial disorders and 
different types of non-mitochondrial disorders. Most families with nuclear mitochondrial disorders showed autosomal recessive inheritance.   De 
novo dominant pathogenic variants were common in families with developmental disorders causing intellectual disability and in epileptic 
encephalopathies.  (d) HPO-Modified Nijmegen Mitochondrial Diagnostic Scores in participants with confirmed genetic diagnoses of 
mitochondrial and non-mitochondrial disorders and in undiagnosed participants.  Participants with ‘probable’, ‘possible’ and ‘partial’ diagnoses 





Figure 4. Comparison of the Human Phenotype Ontology terms in patients with mitochondrial and non-mitochondrial diagnoses. HPO 
ancestor systems for the HPO terms recorded in participants with definite mitochondrial diagnoses and definite non-mitochondrial diagnoses 
(excluding partial diagnoses).   Each column represents one participant (family number in brackets), and those with mitochondrial diagnoses 
(nuclear or mtDNA) are shown on the left side, and those with non-mitochondrial diagnoses are shown on the right side.  Each row represents a 
different HPO ancestor system, listed in order of how frequently they were affected, with the nervous system at the top.  The numbers indicate 
how many of the participant’s HPO terms related to the HPO ancestor system (for example the nervous system or the musculoskeletal system).  
The colours go from green through to red as the number of terms related to the HPO ancestor system increases.  Overall, the pattern of HPO 
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